NCT02654522View on ClinicalTrials.gov

The Use of a Recombinant DNA-based Hyaluronidase to Dissolve Fixed Amounts of Hyaluronic Acid Dermal Fillers

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Dermal Filler
Interventions
DRUG

Hylenex

1-3 hours post injection, the 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U).

All Listed Sponsors
lead

Steve Yoelin M.D. Medical Associates, Inc.

OTHER

NCT02654522 - The Use of a Recombinant DNA-based Hyaluronidase to Dissolve Fixed Amounts of Hyaluronic Acid Dermal Fillers | Biotech Hunter | Biotech Hunter